Rebecca Araujo

Rebecca is a medical writer and editor with experience covering hematology and oncology research and news. Her work has appeared in ASH Clinical News, Blood Cancers Today, DocWire News, GU Oncology Now, and more. Rebecca received her bachelor’s degree in English from Rutgers University.

Articles by Rebecca Araujo

Rebecca AraujoPatient Voice | January 7, 2022
Pain is one of the most common and difficult symptoms to manage experienced by cancer patients.
Read More
Rebecca AraujoPatient Voice | December 23, 2021
Extensive research has been carried out on how oncologists communicate with their patients.
Rebecca AraujoNews | December 28, 2022
Patient navigation is increasingly becoming standard of care in cancer centers, but a new study published in Supportive Care ...
Rebecca AraujoPatient Voice | April 17, 2023
Oral mucosal lesions (mouth ulcers) are a common and debilitating side effect of many anticancer drug treatments.
Rebecca AraujoPatient Voice | April 17, 2023
A recent study looked at how patients with cancer and their caregivers prioritize their unmet needs during treatment.
Rebecca AraujoPatient Voice | November 1, 2021
Yoga is a feasible but as of yet non-efficacious non-pharmacological treatment in cancer survivors with chronic CIPN pain.
Rebecca AraujoBest Practices | December 28, 2022
Patients taking oral anti-cancer therapies require regular monitoring in case of adverse drug reactions. A study of nurses ...
Rebecca AraujoPatient Voice | October 1, 2021
A clinical screening intervention identifies patients with advanced cancer likely to benefit from early palliative care.
Rebecca AraujoPatient Voice | January 24, 2024
Nurses are able to discuss fertility presentation, but they have limited knowledge of relevant clinical practice guidelines.
Rebecca AraujoGU Cancer | December 28, 2022
Cancer-related fatigue affects about 80% of people with colorectal cancer, especially those receiving chemotherapy. But ...
Rebecca AraujoGVHD | September 2, 2021
Chronic GVHD becomes glucocorticoid-refractory or glucocorticoid-dependent in approximately 50% of patients.
Rebecca AraujoGVHD | October 17, 2023
Treatment with belumosudil was associated with organ responses in heavily pretreated patients with chronic graft-versus-host ...
Rebecca AraujoGVHD | October 17, 2023
In a phase 2 trial, treatment with the histone deacetylase inhibitor panobinostat plus tacrolimus and sirolimus was tolerable ...
Rebecca AraujoGVHD | September 2, 2021
Data on cardiac events associated with post-transplant cyclophosphamide are scarce.
Rebecca AraujoPatient Voice | August 13, 2021
Almost 50% of parents of children with cancer in Germany are prone to dysfunctional fear of progression.
Rebecca AraujoBest Practices | December 28, 2022
A new study published in the Journal of Pain and Symptom Management uncovered clinically meaningful cut-points for oncology ...
Rebecca AraujoBest Practices | December 28, 2022
Physical function is increasingly recognized as an important patient-centered and clinical metric in cancer, associated with ...
Rebecca AraujoPatient Voice | April 17, 2023
Mobile health interventions are an acceptable approach that may improve adherence outcomes in patients with cancer.
Rebecca AraujoPatient Voice | April 17, 2023
Endocrine therapy is one of the most common treatments for breast cancers that are hormone positive.
Rebecca AraujoPatient Voice | April 17, 2023
Individuals aged 65 and older are the fastest growing age demographic being diagnosed with cancer.